BCMA is the most attractive target antigen for CAR T cell therapy for MM, and BCMA-CAR T cell therapy has achieved unprecedented responses in recurrent or refractory MM patients, bringing new hope for these patients (17). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.